Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcutis Biotherapeutics filings document regulatory disclosures for a Nasdaq-listed commercial-stage biopharmaceutical company developing and commercializing dermatology treatments. Its Form 8-K reports furnish quarterly and annual financial-results releases, business updates, ZORYVE product-revenue commentary, clinical and regulatory program updates, and securities information for its common stock listed on the Nasdaq Global Select Market.
Arcutis proxy and governance filings cover annual meeting matters, executive compensation, equity awards, board composition, and shareholder voting items. Other material-event disclosures address director changes, compensatory arrangements, consulting or transition agreements, and related governance matters within the company’s public-company reporting framework.
Arcutis Biotherapeutics reported strong growth and a profitable fourth quarter 2025 while raising 2026 sales guidance. Q4 2025 net product revenue for ZORYVE was $127.5 million, up 84% year over year and 29% sequentially, driving total Q4 revenue to $129.5 million versus $71.4 million a year earlier.
Full-year 2025 net product revenue for ZORYVE reached $372.1 million, a 123% increase over 2024, with total revenue of $376.1 million. The company generated Q4 net income of $17.4 million, compared with a $10.8 million loss in Q4 2024, and narrowed its full-year net loss to $16.1 million from $140.0 million.
Arcutis produced $26.2 million of operating cash flow in Q4 and ended 2025 with $221.3 million in cash, cash equivalents, restricted cash, and marketable securities. It raised 2026 net product revenue guidance to a range of $480 million to $495 million and highlighted positive clinical progress and pipeline advancement for ZORYVE and ARQ-234.
Rubric Capital Management and David Rosen report passive ownership of 6.75% of Arcutis Biotherapeutics, Inc. common stock on an amended Schedule 13G. They beneficially own 8,271,577 shares with shared voting and dispositive power and no sole authority.
The ownership percentage is based on 122,492,192 shares outstanding as of October 22, 2025, as disclosed in Arcutis’s Form 10-Q for the quarter ended September 30, 2025. The filers certify the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Prudential Financial, Inc. reported beneficial ownership of 7,079,926 shares of Arcutis Biotherapeutics, Inc. common stock, representing 5.7% of the class as of 12/31/2025.
Prudential has sole voting and dispositive power over 45,000 shares and shared voting power over 6,381,022 shares, with shared dispositive power over 7,034,926 shares. The position is held through subsidiaries including Jennison Associates LLC, The Prudential Insurance Company of America, and Quantitative Solutions LLC. Prudential states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Arcutis.
Arcutis Biotherapeutics executive Masaru Matsuda reported multiple stock sales. On February 2, 2026, he sold blocks of Arcutis common stock at weighted average prices of $24.97 to $25.63, in several transactions disclosed in the filing.
The filing explains that one sale was made to cover tax withholding obligations tied to vesting restricted stock units granted on January 12, 2024. All reported transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on June 5, 2025. Following these trades, Matsuda beneficially owned 110,003 shares of Arcutis common stock in direct form as the company’s SVP, General Counsel and Corporate Secretary.
Arcutis Biotherapeutics executive Patrick Burnett, Executive Vice President and Chief Medical Officer, reported selling Arcutis common stock in two transactions. On February 2, 2026, he sold 3,675 shares at a weighted average price of $25.4984 to cover tax withholding tied to vesting restricted stock units. On February 4, 2026, he sold 9,794 shares at a weighted average price of $25.8064. Both transactions were executed under a Rule 10b5-1 trading plan adopted on December 12, 2024, with a plan end date of February 27, 2026. After these sales, Burnett directly beneficially owned 80,651 shares of Arcutis common stock.
Arcutis Biotherapeutics President and CEO Todd Watanabe, who also serves as a director, sold 19,833 shares of common stock on February 2, 2026 at a weighted average price of $25.4984 per share. The sale was made to cover tax withholding obligations arising from the vesting of previously granted restricted stock units.
After this transaction, Watanabe beneficially owned 721,306 common shares directly. Additional indirect holdings are reported through several entities, including trusts and an LLC, with reported positions of 25,410 shares, 25,410 shares, 57,358 shares, and 124,956 shares, where he disclaims beneficial ownership beyond his pecuniary interest.
Arcutis Biotherapeutics SVP CFO Latha Vairavan reported a small insider sale tied to equity compensation. On February 2, 2026, she sold 1,320 shares of common stock at a weighted average price of $25.4984 per share. According to the footnotes, the sale was made solely to cover tax withholding obligations arising from the vesting of previously granted restricted stock units. Following this transaction, she beneficially owns 63,607 shares of Arcutis common stock directly.
Arcutis Biotherapeutics director Howard G. Welgus sold shares under a pre-set trading plan. On February 2, 2026, he sold 10,000 shares of Arcutis common stock at a weighted average price of $25.0483 per share pursuant to a Rule 10b5-1 plan adopted on March 11, 2025. After this planned sale, he beneficially owns 59,744 shares of common stock directly.
Arcutis Biotherapeutics executive Larry Todd Edwards reported a small insider sale of common stock. On February 2, 2026, he sold 2,052 shares at a weighted average price of $25.4984 per share, solely to cover tax withholding obligations from vesting restricted stock units (RSUs).
The RSUs were granted on January 12, 2024 and vest 25% annually each February 1, beginning in 2025, subject to continued service. After this tax-related sale, Edwards beneficially owns 148,865 shares, including 724 shares purchased under the company’s Employee Stock Purchase Plan on November 30, 2025.
Arcutis Biotherapeutics insider plans stock sale under Rule 144. A holder named Patrick Burnett filed notice to sell 9,794 shares of Arcutis common stock through Merrill Lynch, with an aggregate market value of $252,748.08, on or about 02/04/2026 on the NASDAQ.
The 9,794 shares to be sold were acquired on 02/01/2026 via restricted stock vesting from Arcutis Biotherapeutics. The filing also lists several prior open‑market sales of Arcutis common shares by the same holder over the past three months, with disclosed share amounts and gross proceeds for each transaction.